Trial Profile
Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti_CTLA-4 Monoclonal Antibody
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Expanded access; Therapeutic Use
- Acronyms CheckMate 168
- Sponsors Bristol-Myers Squibb
- 28 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 22 May 2014 New trial record